EHA 2017 | Brewing T-cell therapies for leukemia and lymphoma
David Maloney
• 22 Jun 2017
David Maloney, MD, PhD, from Seattle Cancer Care Alliance, USA gives an overview of current trials using CAR T-cells in leukemia and lymphoma treatment at the European Haematological Association (EHA) 2017 in Madrid, Spain. He highlights three specific companies working on producing similar therapies, Kite, Juno and Novartis, using costimulatory domains with retroviruses or lentiviruses. Despite being restricted to patients who have already failed other therapies, CAR T- cell mediated therapy has shown encouraging results so far.
